
    
      Patients will be randomized 2:1 to study drug versus placebo. Patients will be recruited from
      North American, Europe and Asia. In addition to overall survival, progression free survival,
      responses by RECIST 1.1 criteria and time to tumor progression will be calculated. Safety and
      tolerability will be assessed, as will pharmacodynamics (peripheral blood levels of arginine
      and citrulline), pharmacokinetics (peripheral blood levels of ADI-PEG 20) and immunogenicity
      (antibodies to ADI-PEG 20).
    
  